ArticleSexually transmitted diseases2026
PrEP Prescriptions at 2 Federally Qualified Health Centers.
Article in Sexually transmitted diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
abstract
backgroundPreexposure prophylaxis (PrEP) is a medication that prevents HIV infection. However, PrEP is not equally used by all who would benefit. We examined PrEP disparities by comparing the number of sexually transmitted infections (STIs) and PrEP prescriptions across sex, race, and ethnic groups from 2 federally qualified health centers (FQHCs) in Pinellas County, Florida, and Chicago, Illinois.
methodsWe obtained limited electronic medical record data from January 1, 2023, to December 31, 2023, and identified STI diagnoses (gonorrhea, chlamydia, or syphilis) and PrEP initiation prescriptions. We calculated the PrEP initiation rate for different sex, race, and ethnicity groups; the rate difference in PrEP initiations for each demographic group compared with that in White men; and the ratio of PrEP initiations to STI diagnoses in each group.
resultsOut of a total of 63,591 patients, 1208 (1.9%) were diagnosed with an STI and 88 (0.1%) had PrEP initiation prescriptions. There was no rate difference per 100 people in PrEP initiation among Black and White men, but Hispanic men (-0.11), Black women (-0.14), White women (-0.24), and Hispanic women (-0.25) demonstrated PrEP disparities. When examining the ratio of PrEP initiations to STI diagnoses in each group, White men had (0.42) PrEP initiations per STI diagnosis, with much lower ratios seen for Hispanic men (0.2), Black men (0.13), Black women (0.04), White women (0.03), and Hispanic women (0.02).
conclusionsWhite men had the highest rate of initial PrEP prescriptions. Men overall received PrEP between 3 and 21 times more frequently per STI diagnosis than women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.